AR and Familial prostate cancer: To determine the impact and specificity of AR antagonist treatment on prostate cancer growth, we first assessed the effect of Compound 26 and 30 on cell viability using various pre-clinical models, including AR-positive VCaP cells and AR-negative DU145 and PC3 cells.